As of June 15, 2025, Novacyt SA (ALNOV.PA) reports a Forward P/E of 2.06.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Novacyt SA's Forward P/E to Peers
To better understand Novacyt SA's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Novacyt SA (ALNOV.PA) | 2.06 |
| Probi AB (PROB.ST) | 243.07 |
| Arcticzymes Technologies ASA (AZT.OL) | 88.83 |
| Biofrontera AG (B8F.DE) | 72.66 |
| Bonesupport Holding AB (BONEX.ST) | 63.25 |
| Eurobio Scientific SA (ALERS.PA) | 27.20 |
Compared to its competitors, Novacyt SA's Forward P/E is among the lowest compared to peers, which may suggest undervaluation or market concerns about future earnings.